TIMP3 and neoplasm: In fact, Stefanoli et al. (222) and Wild et al. (223) reported its recurrent methylation (44%), with an increase in metastatic cases (79%) and a corresponding loss of immunolabeling in tumor tissue, whereas two consecutive works by Arnold et al. (206, 214) reported no methylation of TIMP3.